Basic and clinical examinations of latamoxef in neonates and immature infants

Latamoxef (LMOX) was used in the treatment and prophylaxis of infections in neonates and immature infants. The following results were obtained. 1. Mean serum concentrations (bioassay) 30 minutes after a single intravenous injection of about 20 mg/kg of LMOX were 49.9mcg/ml in neonates and 47.3mcg/ml in immature infants aged 0-3 days, 54.1 mcg/ml in neonates and 60.6mcg/ml in immature infants aged 4~7 days, 48.9mcg/ml in neonates and 46.7 mcg/ml in immature infants aged 8-28 days and 62.1 mcg/ml in immature infants aged over 29 days. Six-hour values were 24.1 mcg/ml, 22.5 mcg/ml, 15.9 mcg/ml, 27.2 mcg/ml, 12.9 mcg/ml, 19.1 mcg/ml and 12.8 mcg/ml, respectively. 2. Mean serum concentration half-lives were 6.70 hotirs in neonates and 8.16 hours in immature infants ggcH 0-3 days, 3.68 hours in neonates and 5.83 hours in immature infants aged 4-7 days, 3.06 hours in neonates and 4.47 hours in immature infants aged 8-28 days and 2.59 hours in immature infants aged over 29 days. 3. Adequate Hiniral efficacy can be expected by the intravenous injection of LMOX in doses of 20 mg/kg 1-2 times daily, in neonates and immature infants aged 0�3 days, 20 mg/kg 2�3 times daily, in neonates and immature infants aged 4-7 days and 20 mg/kg 3 times daily, in neonates and immature infants aged 8-28 4. The clinical efficacy of LMOX was good in 5 cases of sepsis (including suspected cases), 5 cases of urinary tract infection, 2 cases of respitary tract infection and 6 cases of intrauterine urfection (including suspected cases). Oiily a case of respiratory tract infections due to P. aeruginosa was thought to be ineffective. 5. Bleeding tendency was noted in 3 cases, which results from secondary vitamin K deficiency should be checked carefully during the administration of LMOX.